Payment overview · 2025
General Payments
$754.47
32 reported records · 14 companies
Healthcare provider profile · identity verified
Robert E Lahasky, M.D.,
Allopathic & Osteopathic Physicians|Family Medicine · NEW IBERIA, LA · NPI 1922086339
Verified facts
What the public records show
CMS Open Payments records show Robert E Lahasky, M.D., received $754.47 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $319.48 | 42.3% | 11 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $121.69 | 16.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.05 | 8.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.32 | 5.7% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $40.02 | 5.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.93 | 4.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.18 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.53 | 2.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.50 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.52 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.64 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.38 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.86 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.37 | 1.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $754.47 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $169.08 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $121.69 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $78.30 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $66.05 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.32 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.32 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $40.02 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.37 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 136 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 148 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 28 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 636 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 554 | 145 |
| Metformin Hcl | Metformin Hcl | 552 | 150 |
| Meloxicam | Meloxicam | 413 | 128 |
| Lisinopril | Lisinopril | 399 | 111 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 293 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 81 |
| Pioglitazone Hcl | Pioglitazone Hcl | 242 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 223 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 49 |
| Omeprazole | Omeprazole | 195 | 45 |
| Furosemide | Furosemide | 190 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 182 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 176 | 55 |
| Montelukast Sodium | Montelukast Sodium | 172 | 46 |
| Gabapentin | Gabapentin | 171 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 42 |
| Jardiance | Empagliflozin | 148 | 25 |
| Alprazolam | Alprazolam | 147 | 22 |
| Simvastatin | Simvastatin | 144 | 40 |
| Farxiga | Dapagliflozin Propanediol | 136 | 28 |
| Losartan Potassium | Losartan Potassium | 135 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 29 |
| Sertraline Hcl | Sertraline Hcl | 106 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 100 | 20 |
| Temazepam | Temazepam | 96 | 13 |
| Buspirone Hcl | Buspirone Hcl | 90 | 22 |
| Glipizide | Glipizide | 86 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 29 |
| Benazepril Hcl | Benazepril Hcl | 81 | 17 |
| Januvia | Sitagliptin Phosphate | 80 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 22 |
| Alendronate Sodium | Alendronate Sodium | 78 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 23 |
| Atenolol | Atenolol | 76 | 19 |
| Memantine Hcl | Memantine Hcl | 74 | 23 |
| Celecoxib | Celecoxib | 73 | 17 |
| Metformin Hcl Er | Metformin Hcl | 69 | 15 |
| Potassium Chloride | Potassium Chloride | 69 | 22 |
| Allopurinol | Allopurinol | 68 | 15 |
| Glimepiride | Glimepiride | 68 | 16 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 64 | 17 |
| Valsartan | Valsartan | 64 | 16 |
| Verapamil Er | Verapamil Hcl | 64 | 18 |
| Tramadol Hcl | Tramadol Hcl | 63 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 28 |
| Carvedilol | Carvedilol | 52 | 16 |
| Linzess | Linaclotide | 52 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 49 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 15 |
| Clonidine Hcl | Clonidine Hcl | 48 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Fenofibrate | Fenofibrate | 45 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 11 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 11 |
| Prednisone | Prednisone | 44 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 14 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | 16 |
| Dutasteride | Dutasteride | 37 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 29 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 35 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Cefdinir | Cefdinir | 31 | 27 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 15 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 18 | 13 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Moexipril Hcl | Moexipril Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $754.47 · 32 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, Azstarys, BREZTRI, COMIRNATY, Cologuard Collection Kit, EVENITY, FARXIGA, JARDIANCE, Kerendia, Ohtuvayre, Ozempic, PREVNAR 20, PROLIA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, VOQUEZNA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error